natgillin/translations-raw huggingface dataset:
Given the minimal involvement of this enzyme in the metabolism of fluvastatin, it is expected that other CYP3A4 inhibitors (e.g. ketoconazole, ciclosporin) are unlikely to affect the bioavailability of fluvastatin. 
Ker je ta encim minimalno vpleten v metabolizem fluvastatina, je malo verjetno pričakovati, da bodo drugi zaviralci CYP 3A4 (npr. ketokonazol, ciklosporin) vplivali na biološko uporabnost fluvastatina.
Studies in renal transplant patients indicate that the bioavailability of fluvastatin (up to 40 mg/day) is not elevated to a clinically significant extent in patients on stable regimens of ciclosporin. 
Študije pri bolnikih po presaditvi ledvic kažejo, da se biološka uporabnost fluvastatina (v odmerkih do 40 mg/dan) ne poveča v klinično pomembni meri pri bolnikih, ki že ustaljeno prejemajo katero od shem s ciklosporinom.
The following wording proposed by the MAH was considered to be acceptable for the CHMP: ‘Lescol is efficacious in monotherapy. 
CHMP je za sprejemljivo štel naslednje besedilo, ki ga je predlagal imetnik dovoljenja za promet z zdravilom: „Zdravilo Lescol je učinkovito pri monoterapiji.
In such situations, the risk of treatment should be considered in relation to the possible benefit and clinical monitoring is recommended. 
V takih razmerah je treba pretehtati tveganje zdravljenja glede na možno korist.
Based on clinical observations, liver function tests are already recommended (see section 4.4). 
Določanje testov jetrne funkcije je priporočeno že na osnovi kliničnih opažanj (glejte poglavje 4.4).
In patients with unexplained diffuse myalgias, muscle tenderness or muscle weakness, and/or marked elevation of creatine kinase (CK) values, myopathy, myositis or rhabdomyolysis have to be considered. 
Pri bolnikih z nepojasnjenimi difuznimi mialgijami, občutljivostjo ali oslabelostjo mišic in/ali izrazitim zvišanjem vrednosti kreatin-kinaze (CK) je treba pomisliti na možnost miopatije, miozitisa ali rabdomiolize.
The benefit and the risk of concurrent treatment should be carefully weighed and these combinations should only be used with caution (see section 4.4). 
Koristi in tveganja sočasnega zdravljenja je treba skrbno pretehtati, pri uporabi te kombinacije zdravil pa je potrebna previdnost (glejte poglavje 4.4).
• Primary hypercholesterolaemia and mixed dyslipidaemia The CHMP agreed with the MAH that additional statements on the exclusion of certain lipoprotein disorders (e.g homozygous variants of familial hypercholesterolaemia and other Fredrickson types with predominant hypertriglyceridemia, or secondary forms of hypercholesterolaemia) are not required in the indication section. 
• Primarna hiperholesterolemija in mešana dislipidemija CHMP se je strinjal z imetnikom dovoljenja za promet z zdravilom, da v poglavju o indikacijah niso potrebne dodatne izjave o izključevanju določenih lipoproteinskih bolezni (npr. homozigotnih različic družinske hiperholesterolemije in drugih Fredricksonovih tipov s prevladujočo hipertrigliceridemijo ali sekundarnih oblik hiperholesterolemije).
Liver function tests and serum CK levels should be monitored. 
Spremljati je treba teste jetrne funkcije in vrednost kreatin-kinaze v serumu.
Like all medicines, Lescol/Lescol XL can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Lescol/Lescol XL neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Presenting features can include dyspnoea, non productive cough and deterioration in general health (fatigue, weight loss and fever). 
Znaki lahko vključujejo dispnejo, neproduktiven kašelj in poslabšanje splošnega stanja (utrujenost, zmanjšanje telesne mase in zvišano telesno temperaturo).
The results from another study in which Lescol XL tablets (80 mg fluvastatin) was administered to renal transplant patients who were on stable ciclosporin regimen showed that fluvastatin exposure (AUC) and maximum concentration (Cmax) were increased 2-fold compared to historical data in healthy subjects. 
Rezultati druge študije, v kateri so dajali tablete Lescol XL (80 mg fluvastatina) po presaditvi ledvic bolnikom, ki so že ustaljeno prejemali katero od shem s ciklosporinom, so pokazali, da sta se pri teh bolnikih izpostavljenost fluvastatinu (AUC) in najvišja koncentracija fluvastatina (Cmax) zvišali za dvakrat v primerjavi z znanimi podatki pri zdravih ljudeh.
Since the available data suggest that there is no serious safety concern for Lescol as compared to placebo, for all renal function categories, the CHMP agreed that doses of >40mg in severe renal impairment would not be contraindicated, but that it would be necessary to initiate these high doses with caution. 
Ker razpoložljivi podatki kažejo, da v nobeni kategoriji ledvične funkcije ni resnih varnostnih zadržkov za uporabo zdravila Lescol v primerjavi s placebom, CHMP meni, da se odmerki > 40 mg pri bolnikih s hudo okvarjenim delovanjem ledvic ne kontraindicirajo, ampak je potrebna previdnost pri uvajanju tako velikih odmerkov.
In healthy volunteers, the use of fluvastatin and warfarin (single dose) did not adversely influence warfarin plasma levels and prothrombin times compared to warfarin alone. 
Pri zdravih prostovoljcih uporaba fluvastatina in varfarina (v enkratnem odmerku) v primerjavi z uporabo samo varfarina ni neugodno vplivala na koncentracijo varfarina v plazmi in na protrombinski čas.
Fluvastatin exerts its main effect in the liver, which is also the main organ for its metabolism. 
Fluvastatin deluje predvsem v jetrih, ki so tudi glavni organ njegove presnove.
− in adult patients with high blood levels of cholesterol 
− pri odraslih bolnikih, ki imajo zvišano raven holesterola,
Lescol/Lescol XL is cleared by the liver, with less than 6% of the administered dose excreted into the urine. 
Zdravilo Lescol/Lescol XL očistijo jetra, pri čemer se manj kot 6 % uporabljenega odmerka izloči v urinu.
The risk of myopathy has been reported to be increased in patients receiving immunosuppressive agents (including ciclosporin), fibrates, nicotinic acid or erythromycin together with other HMG-CoA reductase inhibitors. 
Poročali so, da je tveganje za nastanek miopatije večje pri bolnikih, ki so prejemali imunosupresivna zdravila (vključno s ciklosporinom), fibrate, nikotinsko kislino ali eritromicin sočasno z drugimi zaviralci reduktaze HMG-CoA.
Lescol/Lescol XL can be taken on its own or with other cholesterol-lowering medicines prescribed by your doctor. 
Zdravilo Lescol/Lescol XL lahko jemljete samostojno ali skupaj z drugimi zdravili za zniževanje ravni holesterola, ki vam jih predpiše vaš zdravnik.
Myopathy has rarely been reported with fluvastatin. 
Pri uporabi fluvastatina so redko poročali o miopatiji.
• In elderly (age > 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis. 
• pri starejših bolnikih (starih > 70 let) je treba glede na prisotnost drugih dejavnikov, ki povečujejo nagnjenost k rabdomiolizi, pretehtati v kolikšni meri je potrebno določanje vrednosti kreatin-kinaze.
Therefore it was the recommendation of the CHMP that the starting dose of 40mg uptitrated to 80mg/day, taking into account patient response would be more appropriate from an efficacy and safety perspective. 
Zato je CHMP priporočil, da bi bilo z vidika učinkovitosti in varnosti primerneje, da se začetni odmerek 40 mg povečuje do 80 mg/dan ob upoštevanju bolnikovega odziva.
ITALFARMACO S.p.A. Viale Fulvio Testi, 330 20126 Milano Italy 
Viale Fulvio Testi, 330 20126 Milano Italija
Lescol XL was administered to over 800 patients in three pivotal trials of 24 weeks active treatment duration and compared to Lescol 40 mg once or twice daily. 
Zdravilo Lescol XL je prejemalo več kot 800 bolnikov v treh ključnih preskušanjih, ki so obsegale 24tedensko aktivno zdravljenje in v katerih so uporabo zdravila Lescol XL primerjali z uporabo zdravila Lescol 40 mg enkrat ali dvakrat na dan.
The analyses from the Lescol pooled clinical trial database and the ALERT study presented by the MAH has provided further data regarding the efficacy and safety of fluvastatin 40-80mg in patients with renal impairment. 
Analize zbirke združenih podatkov kliničnih preskušanj zdravila Lescol in študije ALERT, ki jih je predložil imetnik dovoljenja za promet z zdravilom, dajejo nove podatke o učinkovitosti in varnosti 40-80 mg fluvastatina pri bolnikih z okvarjenim delovanjem ledvic.
Fluvastatin treatment slowed the progression of coronary atherosclerosis lesions by 0.072 mm (95% confidence intervals for treatment difference from −0.1222 to −0.022 mm) over 2.5 years as measured by change in minimum lumen diameter (fluvastatin −0.028 mm vs. placebo −0.100 mm). 
Zdravljenje s fluvastatinom je upočasnilo napredovanje lezij koronarne ateroskleroze za 0,072 mm (95-odstotni interval zaupanja za razliko zaradi zdravljenja od -0,1222 do -0,022 mm) v obdobju dveh let in pol na podlagi merjenja spremembe najmanjšega premera svetline (fluvastatin -0,028 mm v primerjavi s placebom -0,100 mm).
Children and adolescents with heterozygous familial hypercholesterolaemia In patients aged < 18 years, efficacy and safety have not been studied for treatment periods longer than two years. 
Otroci in mladostniki s heterozigotno familiarno hiperholesterolemijo Pri bolnikih, starih manj kot 18 let, učinkovitosti in varnosti niso proučevali v več kot dvoletnem obdobju zdravljenja.
This can be avoided if your doctor stops your treatment with fluvastatin as quickly as possible. 
To bi lahko bili zgodnji znaki razgradnje mišic, ki je lahko huda in se ji lahko izognete, če zdravnik čim prej prekine vaše zdravljenje s fluvastatinom.
The primary endpoint of MACE occurred in 21.4% of patients treated with fluvastatin vs 26.7% of patients treated with placebo (absolute risk difference: 5.2%; 95% CI: 1.1 to 9.3). 
Do primarnega cilja opazovanja, to je do pojava pomembnega neželenega srčnega dogodka (MACE), je prišlo pri 21,4 % bolnikov, ki so prejemali fluvastatin, v primerjavi s 26,7 % bolnikov, ki so prejemali placebo (absolutna razlika tveganj: 5,2 %; 95-odstotni interval zaupanja: od 1,1 do 9,3).
Psychiatric disorders Common: 
Psihiatrične motnje pogosti:
Do not use Lescol/Lescol XL after the expiry date which is stated on the carton and blister after [To be completed nationally]. 
Zdravila Lescol/Lescol XL ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu poleg oznake [Izpolni država članica].
Based on the lack of interaction of fluvastatin with other CYP3A4 substrates, fluvastatin is not expected to interact with grapefruit juice. 
Fluvastatin ne deluje medsebojno z drugimi substrati CYP 3A4, zato ni pričakovati interakcij s sokom grenivke.
The data on LDL-C lowering at different time points based on the pooled efficacy analysis from the Lescol XL registration program supports the following recommendation: 
Na podlagi podatkov o nižanju ravni LDL-C v različnih časovnih točkah iz analize učinkovitosti z združenimi podatki programa registracije zdravila Lescol XL se priporoča naslednje:
Administration of fluvastatin to healthy volunteers pre-treated with rifampicin (rifampin) resulted in a reduction of the bioavailability of fluvastatin by about 50%. 
Pri zdravih prostovoljcih, ki so bili prej zdravljeni z rifampicinom (rifampinom), je uporaba fluvastatina zmanjšala biološko uporabnost fluvastatina za približno 50 %.
United Kingdom Novartis Pharmaceuticals UK Ltd (Trading as Sandoz 
Velika Britanija Novartis Pharmaceuticals UK Ltd (Trading as Sandoz Pharmaceuticals) Frimley Business Park
From an efficacy perspective the 80 mg dose provided reliable LDL-C lowering of at least 30% vs baseline at 24 weeks. 
Z vidika učinkovitosti je 80-miligramski odmerek po 24 tednih zagotovil zanesljivo znižanje ravni LDL-C za vsaj 30 % glede na izhodiščno raven.
Do not take Lescol / Lescol XL if you are pregnant or breast-feeding as the active ingredient may lead to harm to your unborn child, and it is not known whether the active ingredient is excreted in human breast milk. 
Če ste noseči ali če dojite, ne jemljite zdravila Lescol/Lescol XL, saj zdravilna učinkovina lahko škoduje nerojenemu otroku in ni znano, ali se zdravilna učinkovina pri ljudeh izloča v materino mleko.
1 Data for Lescol from 12 placebo-controlled trials Data for Lescol XL 80 mg tablet from three 24-week controlled trials 
1 podatki za zdravilo Lescol so iz 12 s placebom kontroliranih preskušanj 2 podatki za tablete zdravila Lescol XL 80 mg so iz treh 24-tedenskih kontroliranih preskušanj
Following oral administration of 40 mg Lescol, the terminal disposition half-life for fluvastatin is 2.3 ± 0.9 hours. 
Po peroralnem odmerjanju 40 mg zdravila Lescol je končni razpolovni čas izločanja fluvastatina 2,3 + 0,9 ure.
Concomitant treatment with other lipid modifying drugs The MAH submitted published data to support the efficacy and safety of Lescol/Lescol XL in combination with nicotinic acid, cholestyramine, or fibrates. 
Sočasno zdravljenje z drugimi zdravili, ki vplivajo na lipide Imetnik dovoljenja za promet z zdravilom je v podporo učinkovitosti in varnosti zdravil Lescol/Lescol XL v kombinaciji z nikotinsko kislino, holestiraminom ali fibrati predložil objavljene podatke.
Glibenclamide (5 to 20 mg daily) increased the mean Cmax and AUC of fluvastatin by 44% and 51%, respectively. 
Uporaba glibenklamida (5 do 20 mg na dan) je zvišala povprečne Cmax fluvastatina za približno 44 % in povečala njegovo AUC za približno 51 %.
The long-term efficacy of Lescol/Lescol XL therapy in childhood to reduce morbidity and mortality in adulthood has not been established. 
Dolgoročna učinkovitost zdravljenja z zdravilom Lescol/Lescol XL v otroštvu glede zniževanja obolevnosti in umrljivosti v odrasli dobi ni bila ugotovljena (glejte poglavje
What Lescol/Lescol XL is and what it is used for Before you take Lescol/Lescol XL How to take Lescol/Lescol XL Possible side effects 
Kaj je zdravilo Lescol/Lescol XL in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Lescol/Lescol XL Kako jemati zdravilo Lescol/Lescol XL Možni neželeni učinki
Elderly population No dose adjustments are necessary in this population. 
Populacija starejših Pri tej skupini bolnikov ni treba prilagajati odmerkov.
As with all other statins physicians should prescribe fluvastatin with caution in patients with predisposing factors for rhabdomyolysis and its complications. 
Kot velja tudi za vse druge statine, morajo biti zdravniki previdni, kadar predpisujejo fluvastatin bolnikom z dejavniki, ki povečujejo nagnjenost k rabdomiolizi in njenim zapletom.
Overall Lescol was safe and well tolerated and the observed safety profile consistent with the known adverse event profile. 
Ugotovljeni varnostni profil je bil skladen z znanim profilom neželenih dogodkov.
If CK levels are significantly elevated at baseline (> 5x ULN), levels should be re-measured within 5 to 7 days later to confirm the results. 
Če je vrednost kreatin-kinaze ob izhodišču pomembno zvišana (na več kot petkratnik zgornje meje normalnih vrednosti - > 5-kratna ZMN), jo je treba 5 do 7 dni pozneje določiti še enkrat za potrditev izvida.
The MAH has also implemented the statement from the EU worksharing Project. 
Imetnik dovoljenja za promet z zdravilom je vnesel tudi izjavo iz projekta „EU Worksharing Project“.
The most commonly reported adverse reactions are mild gastrointestinal symptoms, insomnia and headache. 
Neželeni učinki, o katerih najpogosteje poročajo, so blage prebavne težave, nespečnost in glavobol.
The Product Information (PI) has also been updated according to the CHMP PhVWP Report on HMG CoA reductase inhibitors to include the following adverse events that have been reported with some statins: sleep disturbances, including insomnia and nightmares, memory loss, sexual dysfunction, depression, exceptional cases of interstitial lung disease, 
Glede na poročilo CHMP PhVWP o zaviralcih HMG-CoA-reduktaze so bile posodobljene tudi informacije o zdravilu z vključitvijo naslednjih neželenih učinkov, ki so bili prijavljeni po uporabi določenih statinov: motnje spanja, vključno z nespečnostjo in nočnimi morami, izguba spomina, spolna disfunkcija, depresija, posamezni primeri intersticijske pljučne bolezni, zlasti po dolgoročnem zdravljenju.
Administration of fluvastatin to healthy volunteers pre-treated with fluconazole (CYP 2C9 inhibitor) resulted in an increase in the exposure and peak concentration of fluvastatin by about 84% and 44%. 
Dajanje fluvastatina zdravim prostovoljcem, ki so prej prejemali flukonazol (zaviralec CYP 2C9), je povzročilo povečanje izpostavljenosti fluvastatinu za okrog 84 % in zvišanje najvišje koncentracije fluvastatina za 44 %.
Tingling or numbness of the hands or feet, disturbed or decreased sensibility. 
Zelo redki: mravljinčenje ali odrevenelost dlani ali stopal, moteno ali zmanjšano občutenje.
A variety of changes were identified in toxicity studies that are common to HMG-CoA reductase inhibitors. 
V študijah toksičnosti so opažali različne spremembe, ki so skupni zaviralcem reduktaze HMG-CoA.
Blood and lymphatic system disorders Very rare: 
Bolezni krvi in limfatičnega sistema zelo redki:
Fluvastatin should be administered at least 4 hours after the resin (e.g. cholestyramine) to avoid a significant interaction due to drug binding of the resin. 
Fluvastatin je treba vzeti najmanj 4 ure po zaužitju smole (na primer holestiramina), da ne bi prišlo do pomembne interakcije zaradi vezave zdravila na smolo.
6.4 Special precautions for storage [To be completed Nationally] 
6.4 Posebna navodila za shranjevanje [Izpolni država članica]
If CK has to be measured it should not be done following strenuous exercise or in the presence of any plausible alternative cause of CK increase as this makes the value interpretation difficult. 
Vrednosti kreatinkinaze, če jo je treba določiti, ni primerno določati po naporni telesni dejavnosti ali v prisotnosti kakšnega drugega verjetnega vzroka zvišanja vrednosti kreatin-kinaze, ker bi to otežilo razlago izmerjene vrednosti.
Although there was no clinical evidence that the safety profile of fluvastatin was altered in patients pretreated with fluconazole for 4 days, caution should be exercised when fluvastatin is administered concomitantly with fluconazole. 
Čeprav pri bolnikih, ki so prej 4 dni prejemali flukonazol, ni bilo kliničnih dokazov, da se varnostni profil fluvastatina spremeni, je pri sočasni uporabi fluvastatina s flukonazolom potrebna previdnost.
Bartók Béla út 43-47, 5th Floor, 1114 Budapest, Hungary 
Madžarska Novartis Hungária Kft. Pharma Bartók Béla út 43-47, 5th Floor 1114 Budapest
Lescol/Lescol XL is contraindicated: 
Zdravilo Lescol/Lescol XL je kontraindicirano:
Prior to initiating treatment with Lescol/Lescol XL, patients should be placed on a standard cholesterollowering diet, which should be continued during treatment. 
Pred začetkom zdravljenja z zdravilom Lescol/Lescol XL morajo bolniki začeti s standardno dieto za zniževanje koncentracije holesterola in z njo nadaljevati tudi med zdravljenjem.
The pharmacokinetics of fluvastatin remain unchanged in patients with mild to severe renal insufficiency. 
Farmakokinetika fluvastatina pri bolnikih z blago do težko ledvično insuficienco ostane nespremenjena.
In the Lescol Intervention Prevention Study (LIPS), the effect of fluvastatin on major adverse cardiac events (MACE; i.e. cardiac death, non-fatal myocardial infarction and coronary revascularisation) was assessed in patients with coronary heart disease who had first successful percutaneous coronary intervention. 
V študiji preprečevanja z intervencijo z zdravilom Lescol (Lescol Intervention Prevention StudyLIPS) so ocenili učinek fluvastatina na pomembne neželene srčne dogodke (major adverse cardiac events oz. MACE; to so srčna smrt, miokardni infarkt brez smrtnega izida,in koronarna revaskularizacija) pri bolnikih s koronarno boleznijo srca po prvem uspešnem perkutanem koronarnem posegu.
Creatine kinase measurement 
Določanje kreatin-kinaze
The recommendations that women of childbearing potential have to use effective contraception and that treatment should be discontinued from women who become pregnant while taking Lescol/Lescol XL, has been included. 
Vključena so bila priporočila, da ženske v rodni dobi uporabljajo učinkovito kontracepcijo in da ženske, ki zanosijo med zdravljenjem z zdravilom Lescol/Lescol XL, prekinejo zdravljenje.
The maximum daily dose is 80 mg. 
Najvišji dnevni odmerek je 80 mg.
In this randomised, double-blind, placebo-controlled trial fluvastatin (n=844), given as 80 mg daily over 4 years, significantly reduced the risk of the first MACE by 22% (p=0.013) as compared to placebo (n=833). 
V tej randomizirani, dvojno slepi, s placebom kontroliranem preskušanju je fluvastatin (n=844), ki so ga bolniki prejemali v odmerku 80 mg na dan 4 leta, statistično značilno zmanjšal tveganje za prvi pomemben neželeni srčni dogodek za 22% (p=0,013) v primerjavi s placebom (n=833).
The first study enrolled 29 pre-pubertal boys, 9-12 years of age, who had an LDL-C level > 90th percentile for age and one parent with primary hypercholesterolaemia and either a family history of premature ischaemic heart disease or tendon xanthomas. 
V prvo študijo je bilo vključenih 29 dečkov v predpubertetnem obdobju, starih 9-12 let, ki so imeli vrednosti LDL holesterola nad 90. percentilov za svojo starost in enega od staršev s primarno hiperholesterolemijo, poleg tega pa bodisi družinsko anamnezo prezgodnje ishemične bolezni srca ali kitne ksantome.
Bialport - Produtos Farmacêuticos, S.A. 
Portugalska Bialport - Produtos Farmacêuticos, S.A.
08029 Barcelona Spain 
08029 Barcelona Španija
When Lescol is used in combination with cholestyramine or other resins, it should be administered at least 4 hours after the resin to avoid significant interaction due to binding of the drug to the resin. 
Če se zdravilo Lescol uporablja v kombinaciji s holestiraminom ali drugimi smolami, ga je treba uporabiti vsaj 4 ure po smoli, da se prepreči znatna interakcija zaradi vezave zdravila na smolo.
However, isolated incidences of bleeding episodes and/or increases prothrombin times have been reported very rarely in patients on fluvastatin receiving concomitant warfarin or other coumarin derivatives. 
Vendar so zelo redko poročali o posameznih primerih epizod krvavitev in/ali o podaljšanem protrombinskem času pri bolnikih, ki so jemali fluvastatin in sočasno varfarin ali druge kumarinske derivate.
Gesundheitsproducte GmbH Ruhlandstrasse 5, 83646 Bad Töltz, 
Ruhlandstrasse 5, 83646 Bad Töltz Nemčija
In the LIPS study which was the basis for this indication, the 80 mg daily dose of fluvastatin (i.e., Lescol IR 40 mg BID) was used as starting dose. 
V študiji LIPS, ki je bila osnova za to indikacijo, so kot začetni odmerek uporabili 80 mg fluvastatina na dan (tj. Lescol IR 40 mg dvakrat dnevno).
There is insufficient information on the effects of fluvastatin in newborns / infants. 
O vplivu fluvastatina na novorojenčka/dojenčka ni dovolj podatkov.
Take special care with Lescol/Lescol XL - if you previously had a liver disease. 
Bodite posebno pozorni pri jemanju zdravila Lescol/Lescol XL - če ste že imeli bolezen jeter.
Concomitant administration of fluvastatin with bezafibrate, gemfibrozil, ciprofibrate or niacin (nicotinic acid) has no clinically relevant effect on the bioavailability of fluvastatin or the other lipid-lowering agent. 
Sočasno dajanje fluvastatina z bezafibratom, gemfibrozilom, ciprofibratom ali niacinom (nikotinsko kislino) nima klinično pomembnega vpliva na biološko uporabnost fluvastatina ali katerega od drugih zdravil za zniževanje lipidov.
‘The conventional studies, including safety pharmacology, genotoxicity, repeated dose toxicity, carcinogenicity and toxicity on reproduction studies did not indicate other risks for the patient than those expected due to the pharmacological mechanism of action. 
„Običajne študije farmakološke varnosti, genotoksičnosti, toksičnosti pri ponavljajočih se odmerkih, kancerogenega potenciala, vpliva na sposobnost razmnoževanja ne kažejo tveganja za bolnika, ki bi bilo večje od pričakovanega zaradi farmakološkega mehanizma delovanja.